Journal of AIDS & Clinical Research

Aranzazu Linares-Alarcón

Publications

• Research Article
  One Year Follow-Up of Darunavir/Cobicistat Monotherapy in Pretreated HIV Patients
  Author(s): Lucia Yunquera-Romero, Rocío Asensi-Díez, Juan Carlos del Rio-Valencia, Aranzazu Linares-Alarcón, Isabel Muñoz-Castillo and Manuel Ángel Castaño-CarracedoLucia Yunquera-Romero, Rocío Asensi-Díez, Juan Carlos del Rio-Valencia, Aranzazu Linares-Alarcón, Isabel Muñoz-Castillo and Manuel Ángel Castaño-Carracedo
  
  Introduction: Boosted protease inhibitor monotherapy (PI/r ) : Darunavir/ritonavir (DRV/r) or Lopinavir/ritonavir (LPV/r) monotherapy is only provided in the major treatment guidelines in pre-treated HIV patients to prevent toxicity associated with nucleoside/nucleotide reverse transcriptase inhibitor (NRTIs), reduce costs and simplify antiretroviral treatment. To start PI/r monotherapy, according to GESIDA g uidelines 2016, patients need to meet the following criteria: absence of chronic hepatitis B, plasma viral load <50 copies/ mL for at least 6 months and absence protease inhibitors mutations or previous virologic failures to PI/r. Currently, there are no studies that evaluate the efficacy and safety of DRV/COBI monotherapy. Methods: This prospective study analyzed pretreated HIV patients with DRV/r monotherapy that were switched to DRV/COBI monotherapy. The aim of the study i.. Read More»
  DOI: 10.4172/2155-6113.1000666

  Abstract PDF